OBJECT: Stereotactic radiosurgery (SRS) is an important management option for patients with small- and medium-sized vestibular schwannomas. To assess the potential role of SRS in larger tumors, the authors reviewed their recent experience. METHODS: Between 1994 and 2008, 65 patients with vestibular schwannomas between 3 and 4 cm in one extracanalicular maximum diameter (median tumor volume 9 ml) underwent Gamma Knife surgery. Seventeen patients (26%) had previously undergone resection. RESULTS: The median follow-up duration was 36 months (range 1-146 months). At the first planned imaging follow-up at 6 months, 5 tumors (8%) were slightly expanded, 53 (82%) were stable in size, and 7 (11%) were smaller. Two patients (3%) underwent resection within 6 months due to progressive symptoms. Two years later, with 63 tumors overall after the 2 post-SRS resections, 16 tumors (25%) had a volume reduction of more than 50%, 22 (35%) tumors had a volume reduction of 10-50%, 18 (29%) were stable in volume (volume change < 10%), and 7 (11%) had larger volumes (5 of the 7 patients underwent resection and 1 of the 7 underwent repeat SRS). Eighteen (82%) of 22 patients with serviceable hearing before SRS still had serviceable hearing after SRS more than 2 years later. Three patients (5%) developed symptomatic hydrocephalus and underwent placement of a ventriculoperitoneal shunt. In 4 patients (6%) trigeminal sensory dysfunction developed, and in 1 patient (2%) mild facial weakness (House-Brackmann Grade II) developed after SRS. In univariate analysis, patients who had a previous resection (p = 0.010), those with a tumor volume exceeding 10 ml (p = 0.05), and those with Koos Grade 4 tumors (p = 0.02) had less likelihood of tumor control after SRS. CONCLUSIONS: Although microsurgical resection remains the primary management choice in patients with low comorbidities, most vestibular schwannomas with a maximum diameter less than 4 cm and without significant mass effect can be managed satisfactorily with Gamma Knife radiosurgery.
OBJECT: Stereotactic radiosurgery (SRS) is an important management option for patients with small- and medium-sized vestibular schwannomas. To assess the potential role of SRS in larger tumors, the authors reviewed their recent experience. METHODS: Between 1994 and 2008, 65 patients with vestibular schwannomas between 3 and 4 cm in one extracanalicular maximum diameter (median tumor volume 9 ml) underwent Gamma Knife surgery. Seventeen patients (26%) had previously undergone resection. RESULTS: The median follow-up duration was 36 months (range 1-146 months). At the first planned imaging follow-up at 6 months, 5 tumors (8%) were slightly expanded, 53 (82%) were stable in size, and 7 (11%) were smaller. Two patients (3%) underwent resection within 6 months due to progressive symptoms. Two years later, with 63 tumors overall after the 2 post-SRS resections, 16 tumors (25%) had a volume reduction of more than 50%, 22 (35%) tumors had a volume reduction of 10-50%, 18 (29%) were stable in volume (volume change < 10%), and 7 (11%) had larger volumes (5 of the 7 patients underwent resection and 1 of the 7 underwent repeat SRS). Eighteen (82%) of 22 patients with serviceable hearing before SRS still had serviceable hearing after SRS more than 2 years later. Three patients (5%) developed symptomatic hydrocephalus and underwent placement of a ventriculoperitoneal shunt. In 4 patients (6%) trigeminal sensory dysfunction developed, and in 1 patient (2%) mild facial weakness (House-Brackmann Grade II) developed after SRS. In univariate analysis, patients who had a previous resection (p = 0.010), those with a tumor volume exceeding 10 ml (p = 0.05), and those with Koos Grade 4 tumors (p = 0.02) had less likelihood of tumor control after SRS. CONCLUSIONS: Although microsurgical resection remains the primary management choice in patients with low comorbidities, most vestibular schwannomas with a maximum diameter less than 4 cm and without significant mass effect can be managed satisfactorily with Gamma Knife radiosurgery.
Authors: Douglas Kondziolka; Samuel M Shin; Andrew Brunswick; Irene Kim; Joshua S Silverman Journal: Neuro Oncol Date: 2014-09-28 Impact factor: 12.300
Authors: Ujwal Yeole; A R Prabhuraj; Arimappamagan Arivazhagan; K V L Narasingarao; Vikas Vazhayil; Dhananjaya Bhat; Dwarakanath Srinivas; Bhanumathi Govindswamy; Somanna Sampath Journal: J Neurol Surg B Skull Base Date: 2021-05-23
Authors: Chloe Dumot; Stylianos Pikis; Georgios Mantziaris; Zhiyuan Xu; Rithika Kormath Anand; Ahmed M Nabeel; Darrah Sheehan; Kimball Sheehan; Wael A Reda; Sameh R Tawadros; Khaled Abdel Karim; Amr M N El-Shehaby; Reem M Emad Eldin; Selcuk Peker; Yavuz Samanci; Tehila Kaisman-Elbaz; Herwin Speckter; Wenceslao Hernández; Julio Isidor; Manjul Tripathi; Renu Madan; Brad E Zacharia; Lekhaj C Daggubati; Nuria Martínez Moreno; Roberto Martínez Álvarez; Anne-Marie Langlois; David Mathieu; Christopher P Deibert; Vivek R Sudhakar; Christopher P Cifarelli; Denisse Arteaga Icaza; Daniel T Cifarelli; Zhishuo Wei; Ajay Niranjan; Gene H Barnett; L Dade Lunsford; Greg N Bowden; Jason P Sheehan Journal: J Neurooncol Date: 2022-09-27 Impact factor: 4.506
Authors: Scott G Soltys; Michael T Milano; Jinyu Xue; Wolfgang A Tomé; Ellen Yorke; Jason Sheehan; George X Ding; John P Kirkpatrick; Lijun Ma; Arjun Sahgal; Timothy Solberg; John Adler; Jimm Grimm; Issam El Naqa Journal: Int J Radiat Oncol Biol Phys Date: 2020-12-26 Impact factor: 8.013
Authors: Umberto Tosi; Miguel E Tusa Lavieri; Anjile An; Omri Maayan; Sergio W Guadix; Antonio P DeRosa; Paul J Christos; Susan Pannullo; Philip E Stieg; Andrew Brandmaier; Jonathan P S Knisely; Rohan Ramakrishna Journal: Neurooncol Pract Date: 2021-02-18